Skip to main content

Table 1 Patient demographics and tumor characteristics

From: Regional metastasis to anatomies beyond traditional neck dissection boundaries: a multi-institutional analysis focused on unconventional metastases in oral cancer patients

Variables

N(%)

The overall survival rate

Univariate analysis

Age

  

0.086

 31–59

37(41.6)

43.2

 60–87

52(58.4)

34.6

Gender

  

0.500

 Male

54(60.7)

37.0

 Female

35(39.3)

40.0

Histories of smoking and alcohol

  

0.867

 Yes

49(55.1)

55.1

 No

40(44.9)

35.0

Premalignant mucosal diseases

  

0.257

 Yes

27(30.3)

30.3

 No

62(69.7)

35.5

Prior radio- or chemo-therapies

  

0.011

 Yes

22(24.7)

24.7

 No

67(75.3)

43.3

Treatment status

  

< 0.001

 Primary lesions for treatment (PG)

25(28.1)

56.0

 Staged (secondary) neck dissections (SG)

28(31.5)

53.6

 Recurrent or residual lesions for salvage surgery (RRG)

36(43.8)

13.9

Primary or recurrent site

  

0.005

 Buccal mucosa

7(7.9)

42.9

 Upper gingiva

13(14.6)

30.8

 Lower gingiva

12(13.5)

41.7

 Floor of mouth

5(5.6)

20.0

 Tongue

24(27.0)

37.5

 Retromolar trigone

9(10.1)

0.0

 Lip

6(6.7)

83.3

 Hard palate

13(14.6)

53.8

Unconventional metastatic subsites

  

0.008

 Buccinator

45(50.6)

44.4

 Sublingual

31(34.8)

38.7

 Parotida

13(14.6)

15.4

Pathological grade

  

0.002

 I

4(4.5)

50.0

 II

55(61.8)

49.1

 III

30(33.7)

16.7

Number of metastatic lymph nodes in the unconventional subsites

 

0.087

 1

68(76.4)

42.6

 2

20(22.5)

25.0

 3

1(1.1)

0.0

Lymph nodes size of UMLNs

  

0.003

 0–3 cm

65(73.0)

44.6

 > 3 cm

24(27.0)

20.8

Extranodal extension (ENE) in UMLNs

  

< 0.001

 Yes

28(31.5)

17.9

 No

61(68.5)

47.5

Contralateral metastasis

  

< 0.001

 Yes

27(30.3)

30.3

 No

62(69.7)

50.0

Concurrent with cervical lymph node metastases

  

0.003

 Yes

58(65.2)

65.2

 No

31(34.8)

64.5

Extranodal extension (ENE) in cervical lymph nodes

  

< 0.001

 Yes

21(23.6)

23.6

 No

68(76.4)

48.5

Neck dissection

  

< 0.001

 ISND

18(20.2)

61.1

 IRND

31(34.8)

54.8

 CND

8(9.0)

0.0

 BND

25(28.1)

12.0

 None

7(7.9)

42.9

Anti-EGFR therapy

  

0.957

 Yes

16(18.0)

31.3

 No

73(82.0)

39.7

Postoperative adjuvant therapies

  

0.042

 Radiotherapy

41(46.1)

46.3

 Chemotherapy

3(3.4)

0.0

 Radio-chemotherapies

25(28.1)

32.0

 None

20(22.5)

35.0

  1. NA not available
  2. aIncluding a case which is with both buccinator and parotid metastases,but mostly in the parotid